JPH0358331B2 - - Google Patents
Info
- Publication number
- JPH0358331B2 JPH0358331B2 JP58093890A JP9389083A JPH0358331B2 JP H0358331 B2 JPH0358331 B2 JP H0358331B2 JP 58093890 A JP58093890 A JP 58093890A JP 9389083 A JP9389083 A JP 9389083A JP H0358331 B2 JPH0358331 B2 JP H0358331B2
- Authority
- JP
- Japan
- Prior art keywords
- selenium
- organic compound
- tsel
- administered
- eleostearic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 34
- 239000011669 selenium Substances 0.000 claims description 33
- 229910052711 selenium Inorganic materials 0.000 claims description 33
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 claims description 11
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 claims description 11
- 239000002383 tung oil Substances 0.000 claims description 11
- 150000002894 organic compounds Chemical class 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000001925 catabolic effect Effects 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000001195 anabolic effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 231100000456 subacute toxicity Toxicity 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010010075 Coma hepatic Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 201000003823 descending colon cancer Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 201000001059 hepatic coma Diseases 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229940065287 selenium compound Drugs 0.000 description 2
- 150000003343 selenium compounds Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000005671 trienes Chemical class 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010051676 Metastases to peritoneum Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- -1 at 200-250°C Substances 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940070020 other anabolic agent in atc Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT21552A/82 | 1982-05-28 | ||
| IT8221552A IT8221552A0 (it) | 1982-05-28 | 1982-05-28 | Nuovi composti ad attivita'antineoplastica, procedimetno per la loro preparazione e relative composizioni farmaceutiche. |
| IT20672A/83 | 1983-04-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS591424A JPS591424A (ja) | 1984-01-06 |
| JPH0358331B2 true JPH0358331B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-09-05 |
Family
ID=11183495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58093890A Granted JPS591424A (ja) | 1982-05-28 | 1983-05-26 | 抗腫瘍活性を有する新規化合物、その製造法およびそれを有効成分とする抗腫瘍剤 |
Country Status (3)
-
1982
- 1982-05-28 IT IT8221552A patent/IT8221552A0/it unknown
-
1983
- 1983-05-26 JP JP58093890A patent/JPS591424A/ja active Granted
- 1983-05-27 ZA ZA833870A patent/ZA833870B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS591424A (ja) | 1984-01-06 |
| IT8221552A0 (it) | 1982-05-28 |
| ZA833870B (en) | 1984-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS62230722A (ja) | 肥満および／または関連状態の治療剤 | |
| EP0095663B1 (en) | Organic selenium compounds having an anti-neoplastic activity | |
| WO1990009787A1 (en) | Novel sulfonamides as radiosensitizers | |
| TW200533636A (en) | Prodrugs of selective androgen receptor modulators and methods of use thereof | |
| CA1108170A (en) | Retinoids and their use in preventing carcinogenesis | |
| JPS6323989B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPH05148274A (ja) | ガリウム化合物 | |
| KR960005704B1 (ko) | 인터루킨-1의 방출을 억제하고 인터루킨-1이 매개된 질환을 완화시키기 위한 약제학적 조성물 | |
| CA1330446C (en) | Phenolic thioalkylamides as inhibitors of 5-lipoxygenase | |
| JPH0358331B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| US4378364A (en) | Postoperative treatment of carcinoma patients | |
| JP4598227B2 (ja) | 放射線および化学療法における感受性増強剤である化合物、並びにそれらの製造方法および使用 | |
| JPH04500506A (ja) | Ａｃａｔ酵素をブロックするのに有効な二価リガンド類 | |
| US9328128B2 (en) | Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport | |
| US5162365A (en) | 5-lipoxygenase inhibitors | |
| JP2659428B2 (ja) | テルルおよびセレン誘導体の複合体 | |
| JPS58502000A (ja) | 置換ピロ−ル | |
| Baker et al. | The influence of thyroid stimulation on the incidence of 3-methylcholanthrene-induced tumors | |
| JPS6357519A (ja) | 発癌プロモ−タ−抑制剤 | |
| JPH0339513B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP7394811B2 (ja) | 消化管の栄養吸収を改善する漢方薬組成物、その製造方法及び使用 | |
| US12152047B2 (en) | Anti-cancer gold compounds | |
| JPS5951926B2 (ja) | 制がん剤 | |
| CN118812404A (zh) | 一种维生素d共晶及其制备方法和应用 | |
| JPS58103390A (ja) | Ｎ，Ｎ↑３−ジ−（β−ブロムプロピオニル）−Ｎ↑１，Ｎ↑２−ジスピロトリピペラジニウムの四級塩、その製法及び抗腫瘍医薬組成物 |